NQF OKs 14 infectious disease measures

Infectious diseases lead to complications, death, high costs

NQF is a voluntary consensus standards-setting organization. Any party may request reconsideration of any of the 14 endorsed quality measures listed by submitting an appeal no later than February 6 (to submit an appeal, go to the NQF Measure Database). For an appeal to be considered, the notification must include information clearly demonstrating that the appellant has interests directly and materially affected by the NQF-endorsed recommendations and that the NQF decision has had (or will have) an adverse effect on those interests.

Endorsed Measures

  • 0058: Avoidance of antibiotic treatment in adults with acute bronchitis (NCQA)
  • 0069: Appropriate treatment for children with upper respiratory infection (URI) (NCQA)
  • 0395: Paired Measure: Hepatitis C ribonucleic acid (RNA) testing before initiating treatment (paired with 0396) (AMA-PCPI)
  • 0396: Paired Measure: HCV genotype testing prior to treatment (paired with 0395)(AMA-PCPI)
  • 0398: Hepatitis C: HCV RNA testing at no greater than week 12 of treatment (AMA-PCPI)
  • 0399: Paired Measure: Hepatitis C: Hepatitis A vaccination (AMA-PCPI)
  • 0404: HIV/AIDS: CD4 cell count or percentage performed (NCQA)
  • 0405: HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) prophylaxis (NCQA)
  • 0408: HIV/AIDS: Tuberculosis (TB) screening (NCQA)
  • 0409: HIV/AIDS: Sexually transmitted diseases – Screening for chlamydia, gonorrhea, and syphilis (NCQA)
  • 2079: HIV medical visit frequency (Health Resources and Services Administration - HIV/AIDS Bureau)
  • 2080: Gap in HIV medical visits (Health Resources and Services Administration - HIV/AIDS Bureau)
  • 2082: HIV viral load suppression (Health Resources and Services Administration - HIV/AIDS Bureau)
  • 2083: Prescription of HIV antiretroviral therapy (Health Resources and Services Administration - HIV/AIDS Bureau)